NCT06627647 2026-02-12A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLCAstraZenecaPhase 3 Recruiting878 enrolled